Progressive Corp vs uniQure N.V. Ordinary Shares — how do they compare? Progressive Corp trades at $214.49 (market cap $129.36B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Progressive Corp is far larger — about 87.4× uniQure N.V. Ordinary Shares's market cap, and Progressive Corp pays a 0.18% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| PGR | QURE | |
|---|---|---|
Market Cap | $129.36B | $1.48B |
Volume | 3,501,619 | 2,488,780 |
Sector | Financials | Health |
52-Week High | $236.18 | $70.59 |
52-Week Low | $190.40 | $9.03 |
Typical Hold Time | 81 Days | 0 Days |
Enterprise Value | $137.57B | $728.62M |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
PGR trades at $213.46, down 3.1% on the day, amid mixed earnings results with recent Q3 2026 miss. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and net income margin of 12.85%. Technicals are bullish with moving averages supporting upside, while RSI levels indicate potential overbought conditions. Recent news highlights Progressive's telematics edge and inclusion in dividend-focused articles.
Outlook remains positive with analyst consensus target of $222.23 implying ~4% upside. Key opportunities include sustained underwriting strength and dividend reliability, but risks involve competitive pressures in auto insurance and earnings volatility. The stock's valuation at P/E of 11.18 appears reasonable relative to profitability metrics.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →